Sentence examples for earlier compounds from inspiring English sources

More importantly, the new compound (6b) shows S…arene interaction not shown by any earlier compounds (1, 2 and 3).

Furthermore, there has been a strong focus on chemistry, e.g. in the study of Lowe and Sayle [13] who looked at the question of how much earlier compounds appear in patents before they can also be found in scientific publications.

These findings suggest that the potent anticonvulsant activities of the earlier compounds were due, in part, to the benzyloxyphenyl motif and provide support for the use of the biaryl-linked pharmacophore in future drug design efforts.

By comparison, this novel compound of this study is fundamentally different from these earlier compounds in both structure and function.

But the process and reasoning by which TBB and TBPH were substituted for earlier compounds remains somewhat opaque.

These ASOs contain a phosphorothioate backbone and 2′-MOE (2′-O-methoxy ethyl/phosphorothioate) modifications of the ribose of the first four and last four nucleotides of the ASO, which enhances the affinity for target RNA, increases the plasma stability, and decreases toxicity when compared with earlier compounds.

Researchers led by Dr. Yaghi reported last year in the journal Science that an earlier compound, MOF-5, could absorb hydrogen concentrations of 1percentt by weight at room temperature and a pressure 20 times atmospheric pressure.

Novartis protests that this is not a case of evergreening because the new version is significantly superior in that it is 30 percent easier for the body to absorb than the earlier compound.

An earlier compound, MitoDNP (not shown), combines a TPP-targeting group and dinitrophenol, 21 but differs from MitoDNP-SUM (trigger and caged DNP shown) in two critical ways: the dinitrophenol group is not caged, so it would affect all mitochondria regardless of ROS production, and the dinitrophenol unit is permanently attached to the lipophilic cation.

Early compounds in the series suffered from poor physicochemical properties and oral bioavailability, and the first two clinical candidates failed in initial human studies.

Early compounds were found to produce liver toxicity, however, and development was discontinued.